Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in Guinea pigs

Journal of Investigative Dermatology

Volumn 128, Issue 12, 2008, Pages 2825-2832

  Brans, Richard ^a   Eriksson, Elof ^a   Yao, Feng ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CJ 9 GD; GLYCOPROTEIN D; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GUINEA PIG; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPINAL GANGLION; VIRAL SKIN DISEASE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GANGLIA, SPINAL; GENES, DOMINANT; GUINEA PIGS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS VACCINES; IMMUNIZATION; IMMUNOGLOBULIN G; POLYMERASE CHAIN REACTION; SKIN; SKIN DISEASES; VIRAL ENVELOPE PROTEINS;

EID: 57349087296     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.142     Document Type: Article

References (51)

1. Aldea C, Alvarez CP, Folgueira L, Delgado R, Otero JR (2002) Rapid detection of herpes simplex virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal. J Clin Microbiol 40:1060-2
2. Alenius S, Oberg B (1978) Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs. Arch Virol 58:277-88
3. Augustinova H, Hoeller D, Yao F (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78:5756-65
4. Bernstein DI (2000) Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 18:1351-8
5. Bernstein DI, Stanberry LR (1999) Herpes simplex virus vaccines. Vaccine 17:1681-9
6. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192:2117-23
7. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE et al. (1997) A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 175:16-25
8. Brehm M, Samaniego LA, Bonneau RH, DeLuca NA, Tevethia SS (1999) Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. Virology 256:258-69
9. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr et al. (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331-40
10. Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA et al. (2003) Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect 79:286-90
11. Cunningham AL, Taylor R, Taylor J, Marks C, Shaw J, Mindel A (2006) Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sex Transm Infect 82:164-8
12. Da Costa XJ, Jones CA, Knipe DM (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 96:6994-8
13. Dudek T, Knipe DM (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-9
14. Embil JA, Stephens RG, Manuel FR (1975) Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J 113:627-30
15. Eriksson E, Yao F, Svensjo T, Winkler T, Slama J, Macklin MD et al. (1998) In vivo gene transfer to skin and wound by microseeding. J Surg Res 78:85-91
16. Ghiasi H, Nesburn AB, Wechsler SL (1996) Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 14:107-12
17. Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J (1995) Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 69:8109-13
18. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM et al. (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79:410-8
19. Hubler WR Jr, Felber TD, Troll D, Jarratt M (1974) Guinea pig model for cutaneous herpes simplex virus infection. J Invest Dermatol 62:92-5
20. Hwang YS, Spruance SL (1999) The epidemiology of uncommon herpes simplex virus type 1 infections. Herpes 6:16-9
21. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B et al. (2006) Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 194:561-70
22. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16:96-113
23. Lafferty WE, Downey L, Celum C, Wald A (2000) Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 181:1454-7
24. Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 72:2760-4
25. Liesegang TJ (1991) A community study of ocular herpes simplex. Curr Eye Res 10(Suppl):111-5
26. Lowhagen GB, Tunback P, Andersson K, Bergstrom T, Johannisson G (2000) First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect 76:179-82
27. McKeough MB, Spruance SL (2001) Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol 137:1153-8
28. Meignier B, Longnecker R, Roizman B (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158:602-14
29. Meignier B, Martin B, Whitley RJ, Roizman B (1990) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162:313-21
30. Nguyen LH, Knipe DM, Finberg RW (1992) Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 66:7067-72
31. Park NH, Pavan-Langston D, McLean SL, Lass JH (1980) Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs. Arch Dermatol 116:672-5
32. Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, Francois G et al. (2004) The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 80:185-91
33. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, Kern ER et al. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23:5424-31
34. Roberts CM, Pfister JR, Spear SJ (2003) Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 30:797-800
35. Sawtell NM (1998) The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 72:6888-92
36. Schafer TW, Lieberman M, Everitt J, Came P (1977) Cutaneous herpes simplex virus infection of guinea pigs as a model for antiviral chemotherapy. Ann N Y Acad Sci 284:624-31
37. Spruance SL, Freeman DJ, Sheth NV (1986) Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. Antimicrob Agents Chemother 30:196-8
38. Spruance SL, Kriesel JD (2002) Treatment of herpes simplex labialis. Herpes 9:64-9
39. Spruance SL, McKeough MB (1988) Evaluation of antiviral treatments for recurrent herpes simplex labialis in the dorsal cutaneous guinea pig model. Antiviral Res 9:295-313
40. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG (1987) Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155:914-20
41. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY et al. (2000) Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 30:549-66
42. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652-61
43. Wachsman M, Kulka M, Smith CC, Aurelian L (2001) A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19:1879-90
44. Whitley RJ (2006) Herpes simplex encephalitis: adolescents and adults. Antiviral Res 71:141-8
45. Whitley RJ, Roizman B (2001) Herpes simplex virus infections. Lancet 357:1513-8
46. Whitley RJ, Roizman B (2002) Herpes simplex viruses: is a vaccine tenable? J Clin Invest 110:145-51
47. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ et al. (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-73
48. Yao F, Eriksson E (1999) A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther 10:1811-8
49. Yao F, Eriksson E (2002) Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res 53:127-33
50. Yao F, Theopold C, Hoeller D, Bleiziffer O, Lu Z (2006) Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol Ther 13:1133-41
51. Zheng B, Graham FL, Johnson DC, Hanke T, McDermott MR, Prevec L (1993) Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11:1191-8